Investigating the best treatments for acid reflux in premature infants in the NICU
Official title: Pathophysiological Evidence Driven Management of GERD in Neonatal ICU Infants: Randomized Controlled Trial
Funded at Research Inst Nationwide Children's Hosp · NIH-10927443 · Data updated 2026-11-12
This study is looking to find better ways to diagnose and treat gastroesophageal reflux disease (GERD) in high-risk newborns in the NICU by using special tests and comparing different treatment options to help these little ones feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $633,944 |
| NIH project number | 5R01DK136762-02 |
| Project ID | NIH-10927443 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are high-risk infants under six months corrected age who are symptomatic for GERD while in the NICU.
✕Less likely to help
Patients who are not in the neonatal ICU or those older than six months corrected age may not benefit from this research.
What this research studies
This research focuses on improving the diagnosis and treatment of gastroesophageal reflux disease (GERD) in high-risk infants in the neonatal intensive care unit (NICU). It aims to address the limitations of current symptom-based diagnoses by using objective measures like 24-hour pH-Impedance testing. The study will compare the effectiveness of different therapies, including natural maturation, proton pump inhibitors, and thickened feeds, to determine the best approach for managing GERD in these vulnerable infants. By refining diagnostic criteria and treatment algorithms, the research seeks to provide evidence-based solutions for better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored treatments for GERD in neonatal ICU infants, potentially reducing hospitalization costs and improving health outcomes.
How similar studies have gone: While there have been studies on GERD treatments, this research is novel in its focus on objective diagnostic criteria and specific therapies for high-risk infants.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Jadcherla, Sudarshan R — Research Inst Nationwide Children's Hosp
- Study coordinator: Jadcherla, Sudarshan R
Related research
Other NIH-funded projects on the same topics.
-
Pathophysiology-based GERD management in NICU infants guided by pH-impedance testing
A NICU randomized trial tests how newborns with suspected GERD respond to standard care, acid-suppressing therapy, or thicker feeds guided by objective pH-impedance tests.
-
Using objective testing to guide reflux care for newborns in the NICU
This project compares three approaches—natural maturation, acid-suppressing medicine (PPI), and thickened feeds with added rice—to help NICU infants under six months who have reflux confirmed by 24-hour pH-impedance testing.
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
-
Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia
This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.
-
Shorter antifungal treatment for kids with candidemia
A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.